- Home
- SRZN vs CALC Comparison
SRZN vs CALC Comparison
Compare SRZN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- CALC
- Stock Information
- Founded
- SRZN 2015
- CALC 2011
- Country
- SRZN United States
- CALC United States
- Employees
- SRZN N/A
- CALC N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- CALC Health Care
- Exchange
- SRZN Nasdaq
- CALC Nasdaq
- Market Cap
- SRZN 38.1M
- CALC 40.3M
- IPO Year
- SRZN N/A
- CALC N/A
- Fundamental
- Price
- SRZN $11.70
- CALC $2.94
- Analyst Decision
- SRZN Strong Buy
- CALC Strong Buy
- Analyst Count
- SRZN 1
- CALC 5
- Target Price
- SRZN $45.00
- CALC $18.20
- AVG Volume (30 Days)
- SRZN 51.3K
- CALC 26.3K
- Earning Date
- SRZN 11-06-2024
- CALC 11-13-2024
- Dividend Yield
- SRZN N/A
- CALC N/A
- EPS Growth
- SRZN N/A
- CALC N/A
- EPS
- SRZN N/A
- CALC N/A
- Revenue
- SRZN $10,000,000.00
- CALC N/A
- Revenue This Year
- SRZN N/A
- CALC N/A
- Revenue Next Year
- SRZN N/A
- CALC N/A
- P/E Ratio
- SRZN N/A
- CALC N/A
- Revenue Growth
- SRZN N/A
- CALC N/A
- 52 Week Low
- SRZN $6.00
- CALC $2.05
- 52 Week High
- SRZN $18.17
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- SRZN 48.38
- CALC 44.89
- Support Level
- SRZN $10.20
- CALC $2.73
- Resistance Level
- SRZN $13.28
- CALC $3.22
- Average True Range (ATR)
- SRZN 1.98
- CALC 0.27
- MACD
- SRZN -0.23
- CALC 0.00
- Stochastic Oscillator
- SRZN 20.22
- CALC 22.34
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.